Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entero Therapeutics ( (ENTO) ) just unveiled an announcement.
On July 15, 2025, Entero Therapeutics, ImmunogenX, LLC, and former shareholders of ImmunogenX, Inc. amended their Rescission Agreement to include additional shareholder representations and warranties, such as accredited investor representation. This amendment follows the initial Rescission Agreement intended to unwind a merger agreement dated March 13, 2024, reflecting Entero Therapeutics’ strategic adjustments in its merger activities.
More about Entero Therapeutics
Entero Therapeutics operates in the biotechnology industry, focusing on therapeutic solutions. The company engages in mergers and acquisitions to expand its market presence and enhance its product offerings.
Average Trading Volume: 1,681,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.3M
For an in-depth examination of ENTO stock, go to TipRanks’ Overview page.